OBJECTIVE: To examine interactions between Neuropsychiatric symptoms (NPS) with Pittsburgh Compound B (PiB) and fluorodeoxyglucose positron emission tomography (FDG-PET) in predicting cognitive trajectories. METHODS: We conducted a longitudinal study in the setting of the population-based Mayo Clinic Study of Aging in Olmsted County, MN, involving 1581 cognitively unimpaired (CU) persons aged ≥50 years (median age 71.83 years, 54.0% males, 27.5% APOE ɛ4 carriers). NPS at baseline were assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q). Brain glucose hypometabolism was defined as a SUVR ≤ 1.47 (measured by FDG-PET) in regions typically affected in Alzheimer's disease. Abnormal cortical amyloid deposition was measured using PiB-PET (SUVR ≥ 1.48). Neuropsychological testing was done approximately every 15 months, and we calculated global and domain-specific (memory, language, attention, and visuospatial skills) cognitive z-scores. We ran linear mixed-effect models to examine the associations and interactions between NPS at baseline and z-scored PiB- and FDG-PET SUVRs in predicting cognitive z-scores adjusted for age, sex, education, and previous cognitive testing. RESULTS: Individuals at the average PiB and without NPS at baseline declined over time on cognitive z-scores. Those with increased PiB at baseline declined faster (two-way interaction), and those with increased PiB and NPS declined even faster (three-way interaction). We observed interactions between time, increased PiB and anxiety or irritability indicating accelerated decline on global z-scores, and between time, increased PiB and several NPS (e.g., agitation) showing faster domain-specific decline, especially on the attention domain. CONCLUSIONS: NPS and increased brain amyloid deposition synergistically interact in accelerating global and domain-specific cognitive decline among CU persons at baseline.

1st Department of Medicine Paracelsus Medical University Salzburg Austria

Department of Neurology Franke Global Neuroscience Education Center Barrow Neurological Institute Phoenix Arizona USA

Department of Neurology Mayo Clinic Rochester Rochester Minnesota USA

Department of Psychiatry and Psychology Mayo Clinic Rochester Rochester Minnesota USA

Department of Quantitative Health Sciences Mayo Clinic Rochester Rochester Minnesota USA

Department of Radiology Mayo Clinic Rochester Rochester Minnesota USA

Institute of Sports and Sports Science Karlsruhe Institute of Technology Karlsruhe Germany

International Clinical Research Center St Anne Hospital Brno Czech Republic

Zobrazit více v PubMed

Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh‐Bohmer KA, Norton MC, et al. Point and 5‐year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170–7. 10.1002/gps.1858 PubMed DOI PMC

Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288(12):1475–83. 10.1001/jama.288.12.1475 PubMed DOI

Geda YE, Roberts RO, Knopman DS, Petersen RC, Christianson TJH, Pankratz VS, et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population‐based study. Arch Gen Psychiatry. 2008;65(10):1193–8. 10.1001/archpsyc.65.10.1193 PubMed DOI PMC

Geda YE, Roberts RO, Mielke MM, Knopman DS, Christianson TJ, Pankratz VS, et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population‐based study. Am J Psychiatry. 2014;171(5):572–81. 10.1176/appi.ajp.2014.13060821 PubMed DOI PMC

Geda YE, Knopman DS, Mrazek DA, Jicha GA, Smith GE, Negash S, et al. Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch Neurol. 2006;63(3):435–40. 10.1001/archneur.63.3.435[ PubMed DOI

Wilson RS, Schneider JA, Boyle PA, Arnold SE, Tang Y, Bennett DA. Chronic distress and incidence of mild cognitive impairment. Neurology. 2007;68(24):2085–92. 10.1212/01.wnl.0000264930.97061.82 PubMed DOI

Rosenberg PB, Mielke MM, Appleby BS, Oh ES, Geda YE, Lyketsos CG. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry. 2013;21(7):685–95. 10.1016/j.jagp.2013.01.006 PubMed DOI PMC

Palmer K, Di Iulio F, Varsi AE, Gianni W, Sancesario G, Caltagirone C, et al. Neuropsychiatric predictors of progression from amnestic‐mild cognitive impairment to Alzheimer's disease: the role of depression and apathy. J Alzheimers Dis. 2010;20(1):175–83. 10.3233/jad-2010-1352 PubMed DOI

Pink A, Stokin GB, Bartley MM, Roberts RO, Sochor O, Machulda MM, et al. Neuropsychiatric symptoms, APOE ε4, and the risk of incident dementia: a population‐based study. Neurology. 2015;84(9):935–43. 10.1212/wnl.0000000000001307 PubMed DOI PMC

Ramakers IH, Visser PJ, Aalten P, Kester A, Jolles J, Verhey FRJ. Affective symptoms as predictors of Alzheimer's disease in subjects with mild cognitive impairment: a 10‐year follow‐up study. Psychol Med. 2010;40(7):1193–201. 10.1017/s0033291709991577 PubMed DOI

Kassem AM, Ganguli M, Yaffe K, Hanlon JT, Lopez OL, Wilson JW, et al. Anxiety symptoms and risk of dementia and mild cognitive impairment in the oldest old women. Aging Ment Health. 2018;22(4):474–82. 10.1080/13607863.2016.1274370 PubMed DOI PMC

Krell‐Roesch J, Syrjanen JA, Machulda MM, Christianson TJ, Kremers WK, Mielke MM, et al. Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: the Mayo Clinic Study of Aging. Int J Geriatr Psychiatry. 2021;36(9):1362–9. 10.1002/gps.5528 PubMed DOI PMC

Burhanullah MH, Tschanz JT, Peters ME, Leoutsakos JM, Matyi J, Lyketsos CG, et al. Neuropsychiatric symptoms as risk factors for cognitive decline in clinically normal older adults: the Cache County study. Am J Geriatr Psychiatry. 2020;28(1):64–71. 10.1016/j.jagp.2019.03.023 PubMed DOI PMC

Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA‐AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535–62. 10.1016/j.jalz.2018.02.018 PubMed DOI PMC

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B. Ann Neurol. 2004;55(3):306–19. 10.1002/ana.20009 PubMed DOI

Pink A, Krell‐Roesch J, Syrjanen JA, Vassilaki M, Lowe VJ, Vemuri P, et al. A longitudinal investigation of Aβ, anxiety, depression, and mild cognitive impairment. Alzheimers Dement; 2022. Oct;18(10):1824–31. 10.1002/alz.12504. Epub 2021 Dec 8. PMID: 34877794; PMCID: PMC9174347. PubMed DOI PMC

Pietrzak RH, Lim YY, Neumeister A, Ames D, Ellis KA, Harrington K, et al. Amyloid‐β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study. JAMA Psychiatry. 2015;72(3):284–91. 10.1001/jamapsychiatry.2014.2476 PubMed DOI

Roberts RO, Geda YE, Knopman DS, Pankratz VS, Boeve BF, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58–69. 10.1159/000115751 PubMed DOI PMC

Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4. 10.1212/wnl.43.11.2412-a PubMed DOI

Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC. The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol. 1991. Jul;48(7):725–8. 10.1001/archneur.1991.00530190071018. PMID: 1859300. PubMed DOI

Rey A. L'examen clinique en psychologie. Paris: Presses Universitaires de France; 1964.

Wechsler D. Wechsler memory scale‐revised. New York: The Psychological Corporation; 1987.

Kaplan E, Goodglass H, Brand S. Boston naming test. Philadelphia: Lea & Febiger; 1983.

Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills. 1958;8(3):271–6. 10.2466/pms.8.7.271-276 DOI

Wechsler D. Wechsler adult intelligence scale‐revised. New York: Psychological Corporation; 1981.

Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–94. 10.1111/j.1365-2796.2004.01388.x PubMed DOI

Ivnik RJ, Malec JF, Smith GE, Tangalos EG, Petersen RC, Kokmen E, et al. Mayo's older Americans normative studies: WAIS‐R norms for ages 56 to 97. Clin Neuropsychol. 1992;6(sup001):1–30. 10.1080/13854049208401877 DOI

Ivnik RJ, Malec JF, Smith GE, Tangalos EG, Petersen RC, Kokmen E, et al. Mayo's older Americans normative studies: WMS‐R norms for ages 56 to 94. Clin Neuropsychol. 1992;6(sup001):49–82. 10.1080/13854049208401879 DOI

Ivnik RJ, Malec JF, Smith GE, Tangalos EG, Petersen RC, Kokmen E, et al. Mayo's older Americans normative studies: updated AVLT norms for ages 56 to 97. Clin Neuropsychol. 1992;6(sup001):83–104. 10.1080/13854049208401880 DOI

Malec JF, Ivnik RJ, Smith GE, Tangalos EG, Petersen RC, Kokmen E, et al. Mayo's older Americans normative studies: utility of corrections for age and education for the WAIS‐R. Clin Neuropsychol. 1992;6(sup001):31–47. 10.1080/13854049208401878 DOI

Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI‐Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12(2):233–9. 10.1176/jnp.12.2.233 PubMed DOI

Morris JC, Weintraub S, Chui HC, Cummings J, DeCarli C, Ferris S, et al. The Uniform data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer disease Centers. Alzheimer Dis Assoc Disord. 2006;20(4):210–6. 10.1097/01.wad.0000213865.09806.92 PubMed DOI

Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement. 2017;13(3):205–16. 10.1016/j.jalz.2016.08.005 PubMed DOI PMC

Lowe VJ, Kemp BJ, Jack CR, Senjem M, Weigand S, Shiung M, et al. Comparison of 18F‐FDG and PiB PET in cognitive impairment. J Nucl Med. 2009;50(6):878–86. 10.2967/jnumed.108.058529 PubMed DOI PMC

Jack CR, Wiste HJ, Therneau TM, Weigand SD, Knopman DS, Mielke MM, et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA. 2019;321(23):2316–25. 10.1001/jama.2019.7437 PubMed DOI PMC

Jack CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131(Pt 3):665–80. 10.1093/brain/awm336 PubMed DOI PMC

Tzourio‐Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single‐subject brain. Neuroimage. 2002;15(1):273–89. 10.1006/nimg.2001.0978 PubMed DOI

Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG‐PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7):1207–18. 10.1016/j.neurobiolaging.2009.07.002 PubMed DOI PMC

Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer's disease neuroimaging initiative positron emission tomography core. Alzheimers Dement. 2010;6(3):221–9. 10.1016/j.jalz.2010.03.003 PubMed DOI PMC

Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr. 1995;19(4):541–7. 10.1097/00004728-199507000-00006 PubMed DOI

Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, et al. Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement. 2013;9(5):602–8. 10.1016/j.jalz.2012.12.001 PubMed DOI PMC

Marshall GA, Donovan NJ, Lorius N, Gidicsin CM, Maye J, Pepin LC, et al. Apathy is associated with increased amyloid burden in mild cognitive impairment. J Neuropsychiatry Clin Neurosci. 2013;25(4):302–7. 10.1176/appi.neuropsych.12060156 PubMed DOI PMC

Mori T, Shimada H, Shinotoh H, Hirano S, Eguchi Y, Yamada M, et al. Apathy correlates with prefrontal amyloid β deposition in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2014;85(4):449–55. 10.1136/jnnp-2013-306110 PubMed DOI

Bensamoun D, Guignard R, Furst AJ, Derreumaux A, Manera V, Darcourt J, et al. Associations between neuropsychiatric symptoms and cerebral amyloid deposition in cognitively impaired elderly people. J Alzheimers Dis. 2016;49(2):387–98. 10.3233/jad-150181 PubMed DOI

Babulal GM, Ghoshal N, Head D, Vernon EK, Holtzman DM, Benzinger TL, et al. Mood changes in cognitively normal older adults are linked to Alzheimer disease biomarker levels. Am J Geriatr Psychiatry. 2016;24(11):1095–104. 10.1016/j.jagp.2016.04.004 PubMed DOI PMC

Krell‐Roesch J, Ruider H, Lowe VJ, Stokin GB, Pink A, Roberts RO, et al. FDG‐PET and neuropsychiatric symptoms among cognitively normal elderly persons: the Mayo clinic study of aging. J Alzheimers Dis. 2016;53(4):1609–16. 10.3233/jad-160326 PubMed DOI PMC

Ng KP, Pascoal TA, Mathotaarachchi S, Chung CO, Benedet AL, Shin M, et al. Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology. 2017;88(19):1814–21. 10.1212/wnl.0000000000003916 PubMed DOI PMC

Donovan NJ, Locascio JJ, Marshall GA, Gatchel J, Hanseeuw BJ, Rentz DM, et al. Longitudinal association of amyloid beta and anxious‐depressive symptoms in cognitively normal older adults. Am J Psychiatry. 2018;175(6):530–7. 10.1176/appi.ajp.2017.17040442 PubMed DOI PMC

Gatchel JR, Rabin JS, Buckley RF, Locascio JJ, Quiroz YT, Yang HS, et al. Longitudinal association of depression symptoms with cognition and cortical amyloid among community‐dwelling older adults. JAMA Netw Open. 2019;2(8):e198964. 10.1001/jamanetworkopen.2019.8964 PubMed DOI PMC

Krell‐Roesch J, Syrjanen JA, Vassilaki M, Lowe VJ, Vemuri P, Mielke MM, et al. Brain regional glucose metabolism, neuropsychiatric symptoms, and the risk of incident mild cognitive impairment: the Mayo clinic study of aging. Am J Geriatr Psychiatry. 2021;29(2):179–91. 10.1016/j.jagp.2020.06.006 PubMed DOI PMC

St Sauver JL, Grossardt BR, Leibson CL, Yawn BP, Melton LJ, Rocca WA. Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. Mayo Clin Proc. 2012;87(2):151–60. 10.1016/j.mayocp.2011.11.009 PubMed DOI PMC